| Literature DB >> 29222709 |
Paula Gonçalves Viana1, Anna Barreto Fernandes Figueiredo2, Isabella Dib Ferreira Gremião2, Luisa Helena Monteiro de Miranda2, Isabela Maria da Silva Antonio2, Jéssica Sepulveda Boechat2, Ana Caroline de Sá Machado2, Manoel Marques Evangelista de Oliveira2,3, Sandro Antonio Pereira2.
Abstract
Sporotrichosis occurs worldwide, and the metropolitan region of Rio de Janeiro, Brazil, is a main endemic area, with a large number of human and animal cases in the last 19 years. This mycosis is more frequently described in cats rather than in dogs. There are a limited number of oral antifungal agents for the treatment of sporotrichosis in animals. In this context, the effectiveness of terbinafine in the treatment of sporotrichosis in humans, as well as the promising results of in vitro susceptibility tests, inspired us to use this drug in the therapy of this mycosis in dogs. We reported for the first time the use of terbinafine in the treatment of two dogs with sporotrichosis caused by Sporothrix brasiliensis. Moreover, we provided an overview of therapeutic features of canine sporotrichosis cases reported since the 1960s. One of the dogs presented the fixed cutaneous form of the disease, while the other patient presented hyperemia of the nasal mucosa and respiratory signs only. Terbinafine showed high antifungal activity in vitro against the canine Sporothrix isolates. The dogs were successfully treated with terbinafine, with remission of all clinical signs initially presented. The current reports indicate that this drug can emerge as a therapeutic option for canine sporotrichosis.Entities:
Keywords: Dogs; Sporothrix brasiliensis; Terbinafine; Therapy
Mesh:
Substances:
Year: 2017 PMID: 29222709 DOI: 10.1007/s11046-017-0225-6
Source DB: PubMed Journal: Mycopathologia ISSN: 0301-486X Impact factor: 2.574